Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related NVS
Novartis Reports Two Positive US Phase III Programs in COPD for QVA149, NVA237
Novartis Posts Higher Q1 Profit
Novartis to flex oncology portfolio muscle at ASCO (Seeking Alpha)
Related ZIOP
US Stock Futures Slide Ahead Of Jobless Claims
CAR-T Therapy Stocks Hit Hard Following AACR Data

Analysts at Deutsche Bank downgraded Novartis AG (NYSE: NVS) from “buy” to “hold.” Novartis' shares closed at $63.20 yesterday. Novartis' trailing-twelve-month ROA is 6.24%.

Analysts at Jefferies downgraded ZIOPHARM Oncology (NASDAQ: ZIOP) from “buy” to “hold.” ZIOPHARM's shares closed at $4.44 yesterday. ZIOPHARM's trailing-twelve-month ROE is -110.59%.

Analysts at Wells Fargo downgraded Stifel Financial (NYSE: SF) from “market perform” to “underperform.” Stifel Financial's shares closed at $31.45 yesterday. Stifel Financial's PEG ratio is 0.81.

Brean Capital downgraded IDEX (NYSE: IEX) from “buy” to “hold.” IDEX's shares closed at $45.98 yesterday. IDEX's trailing-twelve-month profit margin is 10.50%.

Latest Ratings for NVS

DateFirmActionFromTo
Mar 2015NatixisUpgradesNeutralBuy
Jan 2015Cowen & CompanyUpgradesMarket PerformOutperform
Dec 2014Morgan StanleyUpgradesUnderweightEqualweight

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (IEX + NVS)

Around the Web, We're Loving...